Drug Profile
Research programme: clindamycin implant - Novalar Pharmaceuticals
Alternative Names: Clindamycin-EVALatest Information Update: 04 Apr 2014
Price :
$50
*
At a glance
- Originator Harvard School of Dental Medicine; The Forsyth Institute
- Developer Novalar Pharmaceuticals
- Class
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dental infections
Most Recent Events
- 25 Jul 2007 Preclinical trials in Dental infections in USA (Parenteral)